Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous hematopoietic stem cells (Shanghai Jiao Tong University School of Medicine)
- Development stage
- Unknown
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous hematopoietic stem cell transplantation (AHSCT) is a cellular therapy being investigated by the Shanghai Jiao Tong University School of Medicine for the treatment of newly diagnosed type 1 diabetes mellitus. The therapeutic approach involves the mobilization of a patient's own hematopoietic stem cells using granulocyte colony-stimulating factor (G-CSF), followed by their collection and cryopreservation. The patient then undergoes a nonmyeloablative conditioning regimen, typically consisting of high-dose cyclophosphamide and antithymocyte globulin (ATG), to deplete the autoreactive T-cells responsible for the destruction of pancreatic beta cells. The harvested stem cells are subsequently reinfused to reconstitute a reset immune system, with the goal of inducing long-term remission and preserving endogenous insulin production as measured by C-peptide levels.
- Other names
- AHSCTautologous nonmyeloablative hematopoietic stem cell transplantationautologous hematopoietic stem cell transplantation
Beyond the preview
Go deeper on autologous hematopoietic stem cells (Shanghai Jiao Tong University School of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous hematopoietic stem cells (Shanghai Jiao Tong University School of Medicine).